Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE-BLMZ: BLMZ Regimen for Rifampicin-Resistant Tuberculosis
NCT07268664Phase 3Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bedaquiline, linezolid, moxifloxacin, pyrazinamide in Tuberculosis (TB), sponsored by Beijing Chest Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bedaquilinelinezolidmoxifloxacinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07268664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268664.